Clinical Trial

Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multicenter Phase I/II study for patients with advanced non-small cell lung cancer who have failed PD-1/L1 therapy, aiming to evaluate the safety of ZG005 in combination with Gecacitinib in this population, as well as the preliminary efficacy of this combination regimen.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-24.
Status change: Not Yet Recruiting → Recruiting 2025-12-30
Trial Details
NCT Number NCT06903377
Lead Sponsor Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Conditions Non-small Cell Lung Cancer
Enrollment 50 participants
Start Date 2025-05-23
Primary Completion 2027-04 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-01-05